Trial Profile
A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Sodium oxybate (Primary)
- Indications Cataplexy; Narcolepsy
- Focus Registrational; Therapeutic Use
- Acronyms REST-On
- Sponsors Avadel Pharmaceuticals; Flamel Technologies
- 08 Nov 2023 Results of Post hoc analyses evaluating efficacy of extended-release once-nightly sodium oxybate vs placebo for daytime sleepiness and disrupted nighttime sleep in narcolepsy type 1 and 2, published in the Sleep
- 08 Nov 2023 According to an Avadel Pharmaceuticals media release, Post-hoc analyses from phase 3 REST-ON trial presented at World Sleep 2023
- 20 Oct 2023 According to an Avadel Pharmaceuticals media release, Post-hoc analyses reinforcing data from the completed pivotal Phase 3 REST-ON trial will be presented at World Sleep 2023, being held from October 20-25, 2023 in Rio de Janeiro, Brazil.